ESCMID

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Retrieved on: 
Friday, April 26, 2024
Biotechnology, Health, Genetics, Science, Research, MALDI, RUO, Yeast, Infection, Gastroenteritis, Piperacillin/tazobactam, HAI, Hospital, Antimalarial medication, Certification, Mycobacterium tuberculosis, Fungal infection, Bacteria, ESCMID, Daptomycin, Patient, Microbiology, Acquisition, Multimedia, Gram-negative bacteria, Diagnosis, Colistin, IVDR, TB, IVD, Sepsis, MBT, Sirius, Vaccine

At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays.

Key Points: 
  • At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays.
  • Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions.
  • Bruker offers additional clinical workflows for rapid functional antibiotic resistance testing, like the MBT STAR®-Carba IVD assay for the detection of carbapenemase activity.
  • Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, commented: “Bruker is committed to innovation in routine microbiology and infectious disease testing.

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Retrieved on: 
Wednesday, April 24, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neisseria gonorrhoeae, Gonorrhea, Randomized controlled trial, World Health Organization, Safety, Woman, ToC, Heart, Ceftriaxone, AMR, ESCMID, Partnership, Zoliflodacin, Azithromycin, Patient, Physician, IM, Failure, HIV, Infection, Clinical trial, Therapy, Organization, Prevalence, Cohort (statistics), Pharmaceutical industry

Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.

Key Points: 
  • Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.
  • GARDP and Innoviva Specialty Therapeutics plan to submit the Phase 3 zoliflodacin data for future publication in a medical journal.
  • Oral zoliflodacin 3g was generally well tolerated and emergent adverse events were comparable between treatment arms (46.2% vs 46.4%).
  • Details for the ESCMID Global 2024 presentations are as follows:
    Title: Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: results of a large global Phase 3 randomized controlled trial
    Session: 05.

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Retrieved on: 
Wednesday, April 17, 2024
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Safety, ESCMID, Political moderate, SPRINT, ECCMID, Medication, Virology, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.
  • The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.
  • Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Retrieved on: 
Thursday, April 25, 2024
Infection, Congress, Recombinant antibodies, SARS-CoV-2, Long, Viral, ELISA, ESCMID, Cytokine, Epitope, Lyme disease, Research, ELISpot, Immunology, Diagnosis, Long COVID, Biomarker, Immunity, Flow cytometry, CD8, Vaccine

The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.

Key Points: 
  • The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
  • "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
  • "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
  • ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.

Beckman Coulter's DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global

Retrieved on: 
Tuesday, April 16, 2024
Infection, HBsAg, Congress, WHO, Hepatitis B, Laboratory, World Health Organization, Hepatitis, Blood, DirectX, ESCMID, DXS, Disease, Senior, Patient, Analyser, Access, Cirrhosis, Hepatitis B virus, Serum, Beckman Coulter, Diagnosis, Chemistry, Liver cancer, Plasma, HBV, Vaccine

Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.

Key Points: 
  • Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.
  • Detection of the viral surface antigen (HBsAg) in serum or plasma indicates an infection caused by hepatitis B virus (HBV).
  • Building on the strengths and global success of the DxI 9000 Analyzer, Beckman Coulter is elevating efficiency and confidence for hepatitis testing.
  • According to Kathleen Orland, Senior Vice President, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics, "By launching these new hepatitis assays on our DxI 9000 Analyzer, we can deliver exceptional quality.

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

Immunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis

Retrieved on: 
Wednesday, April 5, 2023
SIRS, ESCMID, CET, Classification, Pediatric intensive care unit, Notifiable disease, Sepsis, Congress, Real-time, Hospital, ECCMID, Patient, European, Physician, Systemic inflammatory response syndrome, Rush Medical College, RPD, Diagnosis, Poster, ICU, Intensive care unit, European Society of Clinical Microbiology and Infectious Diseases, Rush University Medical Center, Infection, Medical device, Pharmaceutical industry

The poster presentation, entitled "CLARIFYING UNCERTAINTY IN SEPSIS DIAGNOSIS USING A GENE EXPRESSION ASSAY," #P1673, will be presented in-person at ECCMID on April 16th, 2023, in Copenhagen, Denmark.

Key Points: 
  • The poster presentation, entitled "CLARIFYING UNCERTAINTY IN SEPSIS DIAGNOSIS USING A GENE EXPRESSION ASSAY," #P1673, will be presented in-person at ECCMID on April 16th, 2023, in Copenhagen, Denmark.
  • Additionally, Immunexpress will host a presentation entitled "SeptiCyte RAPID, a unique qPCR host response assay for the rapid and early detection of sepsis," at the ECCMID Innovation Theatre on April 17th, 2023, at 12:30 p.m. CET.
  • The 143 indeterminate patients included in the study were reviewed again, requiring a final adjudication of SIRS or sepsis performed by forced diagnosis with SeptiCyte RAPID.
  • By differentiating sepsis from SIRS, care teams are able to more confidently prescribe antibiotics for sepsis patients as an essential part of their care plan."

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Retrieved on: 
Friday, October 7, 2022
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Health Technology, Clinical Trials, LinkedIn, ASM, United States Department of Health and Human Services, Cystic Fibrosis Foundation, Disease, Risk, Biomedical Advanced Research and Development Authority, Founders Fund, Development, Infection, Debridement, Human services, Conference, QIDP, Drug development, Society, Patient, Hospital, Twitter, Mortality, Inflammation, Artificial intelligence, European Society of Clinical Microbiology and Infectious Diseases, Technology, Stenotrophomonas maltophilia, Cystic fibrosis, TKA, Administration, Acinetobacter baumannii, Department, Blood, Antimicrobial resistance, Research, Bacteria, Recurrence, Skin, MDR, Fast Track, Challenge, Gram, ESCMID, Pseudomonas aeruginosa, Poster, Algorithm, Vaccine, Pharmaceutical industry, Wellcome

Peptilogics , a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.

Key Points: 
  • Peptilogics , a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.
  • Data presented demonstrate activity of PLG0206 against multi-drug resistant pathogens and suggest that this novel antimicrobial peptide could potentially address difficult to treat bacterial infections.
  • The poster, titled Activity of the novel engineered antimicrobial peptide PLG0206 against non-fermenting Gram-negative rods, highlights data investigating PLG0206 against isolates Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophili present in skin, urinary, blood, intra-abdominal and respiratory infections.
  • PLG0206 has the potential to rapidly target bacteria and persistent pathogens that produce biofilm and evade conventional antibiotics.

Late-breaking data at ACC.22 with over 1 million patients demonstrates a major gap in guideline adherence resulting in higher mortality for patients with infected CIEDs

Retrieved on: 
Monday, April 4, 2022
Consensus, Risk, Lead, Duke University, Veni, vidi, vici, Greenspan, Anguera, HRS, NYSE, Caregiver, Research, Duke University School of Medicine, AEX, Electrophysiology, American College, Extraction, Solution, Education, PHG, Lexicon, Diagnosis, Mortality, CMS, Infection, Centers for Medicare & Medicaid Services, Senior, Quality of life, ESCMID, ACC, Cardiac electrophysiology, Death, Lead management, Awareness, American College of Cardiology, Journal of the American College of Cardiology, Internal medicine, European Heart Rhythm Association score of atrial fibrillation, Assistant, Safety, Physician, Pharmaceutical industry, Medical device, Medicare, Medicine, Patient

This study highlights the life-threatening nature of device infections and the significant opportunities to improve care in these complex patients.

Key Points: 
  • This study highlights the life-threatening nature of device infections and the significant opportunities to improve care in these complex patients.
  • The opportunity to ensure all patients have access to guideline-recommended care is not only imperative, but life-saving for patients across the world.
  • Each year one million CIEDs are implanted worldwide [4] (which include pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization devices).
  • Low Rates Of Guideline Directed Care Associated With Higher Mortality In Patients With Infections Of Pacemakers And Implantable Cardioverter Defibrillators.

Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID

Retrieved on: 
Wednesday, December 8, 2021
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, Medical microbiology, Disease, CDI, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, News, Risk factor, ESCMID, Recurrence, Goldenberg, Dis, Clostridioides difficile infection, Microbiota, Infection, PMID, Acquisition, Plasma protein binding, Clostridioides, Meta-analysis, ECDC, IDSA, Patient, IBD, Consultant, Mortality, OTC, Human, Tesco international operations, Clostridium difficile, Systematic review, Vancomycin, European Centre for Disease Prevention and Control, Lancet, University, Tablet, Guideline, Society, Wes Tillott, Fidaxomicin, CDAD, Health care, MD, Adult, RNA, Clinical trial, Trial of the century, Vaccine, Pharmaceutical industry, DIFICLIRTM, Tillotts, Zeria, DIFICLIRTM, TILLOTTS, ZERIA

Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.

Key Points: 
  • Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.
  • European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
  • Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
  • Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad.